U.S. markets open in 5 hours 40 minutes
  • S&P Futures

    4,109.00
    -10.50 (-0.25%)
     
  • Dow Futures

    33,567.00
    -115.00 (-0.34%)
     
  • Nasdaq Futures

    13,810.50
    -19.00 (-0.14%)
     
  • Russell 2000 Futures

    2,229.50
    -9.70 (-0.43%)
     
  • Crude Oil

    58.77
    -0.55 (-0.93%)
     
  • Gold

    1,740.20
    -4.60 (-0.26%)
     
  • Silver

    25.15
    -0.18 (-0.71%)
     
  • EUR/USD

    1.1879
    -0.0025 (-0.21%)
     
  • 10-Yr Bond

    1.6660
    0.0000 (0.00%)
     
  • Vix

    17.44
    +0.49 (+2.89%)
     
  • GBP/USD

    1.3730
    +0.0025 (+0.18%)
     
  • USD/JPY

    109.4670
    -0.1830 (-0.17%)
     
  • BTC-USD

    60,881.84
    +1,047.08 (+1.75%)
     
  • CMC Crypto 200

    1,303.48
    +75.94 (+6.19%)
     
  • FTSE 100

    6,880.13
    -35.62 (-0.52%)
     
  • Nikkei 225

    29,538.73
    -229.33 (-0.77%)
     

2 Falling Knives for Investors to Consider

  • Oops!
    Something went wrong.
    Please try again later.
GuruFocus.com
  • Oops!
    Something went wrong.
    Please try again later.

When shares of companies lose more than 59% of their value in a year, they are called falling knives. These stocks spark the interest of some investors who believe they can make a considerable return following an expected rebound.

This category of investors is also aware that investing in falling knives carries a remarkable risk of a severe loss because the quick detioration in the stock is usually a sign of financial trouble for the company. But investors can reduce such risk if they pick stocks with a moderate to low financial burden, namely, a debt-equity ratio below 0.50.


Having said that, investors should consider the falling knives that have also received an overweight recommendation rating from Wall Street sell-side analysts, which increases expectations for unbelievable returns as the rating indicates these stocks will outperform.

Savara

Shares of Savara Inc. (NASDAQ:SVRA) closed at $1.33 on Monday for a market capitalization of $54.81 million. The stock declined 84% over the last 12 months through Dec. 2.

The Austin, Texas-based biotech developer of orphan drugs for lung diseases has a debt-equity ratio of 0.24, which is above the industry median of 0.11.

GuruFocus assigned a moderate rating of 5.2 out of 10 for the company's financial strength, but a very low rating of 1 out of 10 for its profitability. Thus, investors must be careful with this stock.

The closing price on Monday was below the 200- and 100-day simple moving average lines, but still above the 50-day line. The 52-week range was 69 cents to $11.96.

The price-book ratio is 0.51 compared to the industry median of 3.63.

The 14-day relative strength index of 69 suggests the stock is still far from oversold levels.

Wall Street issued an overweight recommendation rating with an average target price of $5.25, reflecting 304% upside from Monday's closing share price.

Intelsat

Shares of Intelsat S.A. (NYSE:I) closed at $6.24 per share on Monday for a market capitalization of $879.84 million. The stock declined 73% over the past 12 months through Dec. 2.

The Luxemburg-based provider of satellite communication services has a debt-equity ratio of -2.96 versus the industry median of 0.58.

GuruFocus assigned a low rating of 2 out of 10 for the company's financial strength, but a moderate rating of 5 out of 10 for its profitability.

The closing price on Monday was below the 200-, 100- and 50-day simple moving average lines. The 52-week range was $5.55 to $27.29.

The price-sales ratio is 0.42 versus the industry median of 1.41.

The 14-day relative strength index of 19 suggests the stock is oversold.

Wall Street sell-side analysts issued an overweight recommendation rating and have established an average target price of $20.50, reflecting 230% upside from Monday's closing price.

Disclosure: I have no positions in any securities mentioned.

Read more here:



Not a Premium Member of GuruFocus? Sign up for a free 7-day trial here.

This article first appeared on GuruFocus.